Objective. Transcription factor p63, of the p53 family, regulates cell proliferation, survival, and apoptosis in various cells and tissues. This study was undertaken to examine the expression and roles of p63 transcript variants in the mouse growth plate and articular chondrocytes.
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Objective. Transcription factor p63, of the p53 family, regulates cell proliferation, survival, and apoptosis in various cells and tissues. This study was undertaken to examine the expression and roles of p63 transcript variants in the mouse growth plate and articular chondrocytes.
Methods. For in vivo analyses, we generated Cremediated TAp63a-transgenic and TAp63g-transgenic mice. To induce tissue-specific overexpression or deletion in chondrocytes, chondroprogenitor cells, or early limb bud mesenchymal cells, we used Col2a1-Cre, Sox9-Cre, and Prx1-Cre mice, respectively. We analyzed osteoarthritis (OA) development with aging or surgically induced instability in Prx1-Cre;p63 fl/fl (P-conditional knockout) mice. Results. Among major variants, TAp63a and TAp63g are highly expressed in mouse primary costal and articular chondrocytes. The p63 protein was predominantly localized in the hypertrophic zone of the embryonic limb cartilage, and in the middle zone of articular cartilage. No obvious change was observed in skeletal growth of TAp63a-transgenic mice, Sox9-Cre;p63 fl/fl , or P-conditional knockout mice, while that of TAp63g-transgenic mice was impaired due to ectopic apoptosis and the resulting decreased number of chondrocytes. Expression of proapoptotic genes including bax, noxa, puma, and fas was increased in TAp63g-transgenic mouse chondrocytes, and their transcription was probably sustained by p53 in p63-conditional knockout mouse chondrocytes because both proteins were coexpressed in the growth plate. In contrast, p53 was expressed in the superficial zone of articular cartilage, differently from p63. Notably, P-conditional knockout mice showed significant resistance to OA development, with suppression of chondrocyte apoptosis in the aging and surgical models.
Conclusion. We demonstrated regulation of chondrocyte survival in articular cartilage by p63.
Skeletal growth is achieved by endochondral ossification in the growth plate cartilage with orderly columnar arrays of resting, proliferative, and hypertrophic zones of chondrocytes (1) . During the process, the cartilage enlarges through chondrocyte proliferation and matrix production (1) . Chondrocytes then stop proliferating, become hypertrophic, produce type X collagen, and undergo apoptotic cell death (1) . The cartilage matrix left behind provides a scaffold for osteoblasts to form bone tissues with blood vessels (1) . A recent study showed that parathyroid hormone/parathyroid hormone-related protein receptor signaling suppresses chondrocyte apoptosis during endochondral ossification (2) ; however, the molecular mechanisms regulating chondrocyte apoptosis are poorly understood.
In adulthood, cartilage plays essential roles as a major component of articular joints. Cartilage degeneration leads to osteoarthritis (OA), which is the most common joint disorder. Recent studies using mouse models of OA have revealed that several phenomena, including excessive production of cartilage matrix-degrading proteases and pathologic endochondral ossification, are involved in OA development (3) . Apoptosis is observed in OA cartilage as well as in growth plate cartilage (4) (5) (6) (7) (8) (9) . However, whether chondrocyte apoptosis is a cause or a result of cartilage degeneration in OA is still a subject of controversy (10) .
The transcription factor p63, a member of the p53 family, is essential for the normal formation of epidermis and limbs (11, 12) , as well as a potent regulator of cell proliferation, survival, apoptosis, and senescence in various cells and tissues (13) . The p63 gene encodes 2 major protein isoforms, TAp63 and DNp63. The TAp63 form contains an N-terminal transactivation (TA) domain, whereas the DNp63 form lacks this domain (14) . Although the DNp63 form was previously believed to be dominant negative, it has become clear that it has transcriptional activities. Both TAp63 and DNp63 can be alternatively spliced at the 3 0 -terminus to produce a-, b-, and g-isoforms (15) . These various isoforms make studying p63 more complicated.
Previous studies have shown that p63-deficient mice are born with a shiny, transparent skin and die several hours after birth, possibly because of dehydration (11, 12) . Skin formation is severely impaired in p63-deficient mice, and the target genes of p63 in epidermal development and differentiation have been identified (16) (17) (18) (19) (20) (21) . Another remarkable feature of p63-deficient mice is limb defects. In p63-deficient neonates, the fore limbs are truncated and the hind limbs are absent (11, 12) . In the fore limbs of the p63-homozygous mutants, all distal components (autopods) are absent, whereas mid components (zeugopods) are heterogeneously defective and proximal components (stylopods) are hypoplastic. According to previous reports, the limb defects in p63-homozygous mutants are mainly the result of a defect in the apical ectodermal ridge and the subsequent impairment of limb bud formation (11, 12) . Recent studies have shown that p63 is expressed in chondrocyte cell lines and that transgenic overexpression of p63 can alter in vivo chondrocyte differentiation (22) (23) (24) . However, expression of each p63 isoform has not been examined in primary chondrocytes or cartilage tissues, and natural roles of p63 in skeletal development are still unknown since loss-offunction studies have not been performed.
With regard to articular cartilage, a recent genomewide association study (GWAS) identified a singlenucleotide polymorphism (SNP) with OA susceptibility in the human p63 gene (25) , indicating that p63 may be involved in OA pathophysiology. Nevertheless, the expression and function of p63 in articular cartilage are still unknown. In the present report, we describe the expression of p63 transcript variants in chondrocytes, and their functions during endochondral ossification and articular cartilage homeostasis using conditional knockout mice and conditional transgenic mice.
MATERIALS AND METHODS
Cell cultures. Primary costal chondrocytes were isolated from the ribs of C57BL/6 neonates, and primary articular chondrocytes were isolated from 6-day-old C57BL/6 mice as described previously (26) . Primary chondrocytes were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), penicillin (100 units/ml), and streptomycin (100 mg/ml). ATDC5 cells (RIKEN BRC) were maintained in DMEM and F-12 (1:1) with 5% FBS, penicillin (100 units/ml), and streptomycin (100 mg/ml), and differentiated with insulin-transferrin-sodium selenite supplement (Sigma) for 3 weeks.
Mice. We performed all experiments according to a protocol approved by the Animal Care and Use Committee of the University of Tokyo. All genetically modified strains were backcrossed to C57BL/6J. Mice were placed in plastic cages with sawdust bedding in a specific pathogen-free facility, with 4-5 animals per cage. The room had a 12-hour light/dark cycle and was kept at a constant temperature (18-228C). Mice were allowed to move freely in the cages and had free access to food and water. Transgenes were constructed for generation of conditional transgenic mice. DNA purification and microinjection were performed according to standard protocols. To confirm the p63 overexpression or knockout, we examined levels of p63 protein and messenger RNA (mRNA) in costal chondrocytes and in limb cartilage obtained from each embryo, respectively. Primer sequences for genotyping are shown in Supplementary Histologic analyses. We performed double staining of skeletons of mouse embryos with a solution containing alizarin red S and Alcian blue 8GX (Sigma) after fixation in 99.5% ethanol. Hematoxylin and eosin (H&E) staining was done according to standard protocols after fixation in 4% paraformaldehyde buffered with phosphate buffered saline. For immunohistochemistry, we incubated the sections with antibodies to p63 (1:100, 4A4; Santa Cruz Biotechnology), p53 (1:100; Santa Cruz Biotechnology), ADAMTS-5 (1:100; Santa Cruz Biotechnology), matrix metalloproteinase 13 (MMP-13) (1:200; Chemicon), promyelocytic leukemia (PML) (1:100; Abcam), p16 INK4a (1:100; Abcam), plasminogen activator inhibitor 1 (PAI-1) (1:100; Abcam), and Dec1 (1:100; Invitrogen). For TUNEL staining, we used an In Situ Cell Death Detection Kit (Roche), and the number of positive cells was counted using BZ II analyzer software in BZ-8100 (Keyence). For bromodeoxyuridine (BrdU) labeling, we injected BrdU (Sigma) intraperitoneally into pregnant mice 4 hours prior to euthanization, and the sections were stained using antibodies to BrdU (Roche) and Alexa Fluor 488 (Molecular Probes). For radiologic analysis, plain radiographs were taken using a soft Xray apparatus (Softex CMB-2).
Human samples. We obtained samples of human articular cartilage from 3 different individuals undergoing total knee arthroplasty. Written informed consent was obtained from all 3 individuals, and approval was provided by the ethics committee of the University of Tokyo.
Construction of expression vectors. We amplified coding sequences of TAp63a, TAp63g, and p53 from mouse complementary DNA (cDNA), and cloned them into pcDNA3.1 vector (Invitrogen). We constructed a small interfering RNA (siRNA) vector for the mouse p53 gene (nucleotides 696-716) with piGENEmU6 vector (iGENE Therapeutics). DNA sequencing was used to verify each construct.
Quantitative polymerase chain reaction (PCR). Total RNA was isolated with an RNeasy Mini kit (Qiagen), and 1 mg of total RNA was reverse transcribed with a QuantiTect RT kit (Qiagen) according to the manufacturer's protocols. Quantitative PCR was performed with a Thermal Cycler Dice (Takara) using FastStart Universal SYBR Green Master (Roche). The mRNA copy number for each gene of interest was calculated using a standard curve generated from serially diluted plasmids containing PCR amplicon sequences. The copy number was normalized to mouse total RNA (Applied Biosystems), with mouse GAPDH as the internal control. All reactions were performed in triplicate.
OA experiments. To analyze OA development with aging, p63
fl/fl and P-conditional knockout male mice were reared for 18 months and killed for analysis. To produce a surgical model of OA, we performed a surgical procedure on 8-week-old p63
fl/fl and P-conditional knockout male mice as described previously (27) . Under general anesthesia, the medial collateral ligament and the medial meniscus were resected under a surgical microscope. Six p63 fl/fl and 8 P-conditional knockout mice were subjected to surgery, and all were analyzed 8 weeks after surgery. We used the Osteoarthritis Research Society International (OARSI) system (28) to quantify severity of OA in the left knee joints; all OARSI assessments were made by a single observer in a blinded manner. The femoral and tibial surfaces of the medial compartment were evaluated. OA grade was determined on a scale of 0-6 depending on the depth of cartilage degeneration, and OA stage was determined on a scale of 1-4 depending on the surface area of the degraded cartilage irrespective of the underlying OA grade. Histologic scores were calculated by multiplying the grade and the stage (score 5 grade 3 stage), as previously described (28) . The mean scores on the 2 surfaces in 3 slides per mouse were used.
Luciferase assays. We amplified proximal promoters of BAX (from 2897 to 18 bp relative to the transcription start site), NOXA (from 21,000 to 0 bp), PUMA (from 21,000 to 11,572 bp), and FAS (from 21,000 to 1970 bp) from human genomic DNA, and cloned them individually into a pGL4. 10[luc2] vector (Promega). Mutant constructs that lack the p53 response element were created by PCR. ATDC5 cells were plated at 10,000 cells/well on 48-well plates 24 hours before transfection. In each well, 100 ng of the pGL4 reporter plasmid, 50 ng of the expression vector, and 3 ng of the pRL-TK (Promega) internal control plasmid were cotransfected using 0.8 ml of Lipofectamine 2000 (Invitrogen). After 48 hours of transfection, cells were harvested and analyzed using a Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instruction. All data are shown as a ratio of firefly luciferase activity to Renilla luciferase activity.
Other analysis. We performed real-time reverse transcriptase-PCR (RT-PCR) and histologic analyses as previously described (29) (30) (31) . Primer sequences for real-time RT-PCR are shown in Supplementary Statistical analysis. To assess the statistical significance of experimental data, we used Student's unpaired 2-tailed t-test for comparisons between 2 groups, and Tukey's post hoc test for comparisons between multiple groups. P values less than 0.05 were considered significant.
RESULTS
Expression of p63 during mouse chondrocyte differentiation. We initially designed the mouse primer sets specific for TA or DN forms, and for a, b, or g, to determine the level of mRNA for each p63 transcript variant in chondrocytes ( Figure 1A ). Among the N-terminal variants, the TA form was abundantly expressed, while expression of the DN form was low in mouse primary costal and articular chondrocytes ( Figure 1B ). Among the Cterminal variants, a and g were dominantly expressed, while b expression was hardly detected ( Figure 1B ). These data indicate that TAp63a and TAp63g are the major variants in both costal and articular chondrocytes in mice. Similarly, the expression of TAp63a and TAp63g increased during differentiation of mouse chondrogenic ATDC5 cells ( Figure 1C ). In the tibial limb cartilage of mouse embryos, p63 protein was detected primarily in the hypertrophic zone and weakly in the proliferative zone ( Figure 1D ). In the knee articular cartilage of an 8-weekold wild-type mouse, p63 protein was strongly expressed in the middle layer, while it was weakly expressed in the superficial and deep layers ( Figure 1E ).
When tissues other than cartilage were assessed, p63 protein was scarcely detected in meniscus, synovium, or subchondral bone (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39976/abstract). We further examined p63 expression in human articular cartilage surgical specimens obtained from 3 patients undergoing total knee arthroplasty. Similar to the pattern of expression in mouse cartilage, intensive staining for p63 protein was detected in the middle layer, and weak staining was detected in the superficial and deep layers ( Figure 1F ).
Skeletal development of Col2a1-Cre;CAG-EGFPTAp63a (a-conditional transgenic) and -TAp63g mouse embryos. To determine the physiologic roles of TAp63a and TAp63g during skeletal growth, we first generated conditional transgenic mice that express TAp63a under the control of the CAG promoter after excision of the loxP-flanked (floxed) enhanced green fluorescent protein (EGFP) gene by Cre recombinase (CAG-EGFP-TAp63a) (Supplementary Figure 2A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.39976/abstract). To overexpress TAp63a specifically in the chondrocyte lineage, we mated CAG-EGFP-TAp63a mice with type II collagen (Col2a1) promoter-driven Cre-transgenic mice (Col2a1-Cre) (32) . The conditional transgenic mice generated (a-conditional 600 TANIGUCHI ET AL transgenic mice) grew normally without obvious skeletal abnormality (Supplementary Figure 2B) . Real-time RT-PCR and immunostaining confirmed the enhanced expression of p63 at both the mRNA and protein levels, respectively, in a-conditional transgenic mouse chondrocytes, respectively (Supplementary Figures 2C and D Figures 2E-G) . We next generated conditional transgenic mice that express TAp63g under the control of the CAG promoter after excision of the floxed EGFP gene by Cre recombinase (CAG-EGFP-TAp63g) (Figure 2A) , and mated them with Col2a1-Cre mice to overexpress TAp63g specifically in the chondrocyte lineage. The conditional transgenic mice generated (Col2a1-Cre;-CAG-EGFP-TAp63g [g-conditional transgenic] mice) showed impaired skeletal growth in the embryonic stages ( Figure 2B) , and died soon after birth, probably due to respiratory dysfunction. We confirmed the enhanced expression of p63 in g-conditional transgenic mouse chondrocytes by real-time RT-PCR ( Figure 2C ) and immunostaining ( Figure 2D ).
Histologic analyses showed that g-conditional transgenic mouse embryos were shorter than control littermate (g-control) embryos ( Figure 2E ). Von Kossa's staining, Safranin O staining, and immunofluorescence staining with antibodies to Cola1(X) and MMP-13 showed no obvious difference between g-conditional transgenic mice Figure 2 . Skeletal development of chondrocyte-specific TAp63g-transgenic mouse embryos. A, Transgene construct of CAG-EGFP-TAp63g. Transgenic mice express TAp63g in a Cre recombinase-dependent manner. B, Double staining with alizarin red and Alcian blue of the whole skeleton (top), front paws (middle), and hind paws (bottom) of CAG-EGFP-TAp63g (g-control) and Col2a1-Cre;CAG-EGFP-TAp63g (gconditional transgenic [g-cTg]) littermate mouse embryos on day 17.5 of gestation (E17.5). Bars 5 1 mm. C, Levels of mRNA for p63g in primary costal chondrocytes from g-control and g-conditional transgenic mouse embryos on E17.5. Bars show the mean 6 SD of 3 wells per group. * 5 P , 0.05. D, Immunostaining for p63 in the proximal tibias of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars 5 50 mm. E, Hematoxylin and eosin staining of whole humeri from g-control and g-conditional transgenic littermate mouse embryos on E17.5. Red, blue, and green bars indicate layers of proliferative zone, hypertrophic zone, and bone area, respectively. Bars 5 100 mm. F, Von Kossa's staining of the proximal tibias of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars 5 100 mm. G, Safranin O staining and immunofluorescence staining with antibodies to type X collagen a1 chain (Cola1[X]) and matrix metalloproteinase 13 (MMP-13) in the proximal tibias of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars 5 100 mm. H, DAPI and bromodeoxyuridine (BrdU) staining of the proximal tibias of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars 5 50 mm. I, Number of chondrocytes (left) and percent of BrdU-positive cells (right) in 1,000 mm 2 of the proximal tibias of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars show the mean 6 SD of 3 slides per group. * 5 P , 0.05. J, TUNEL staining of g-control and g-conditional transgenic littermate mouse embryos on E17.5. Bars 5 100 mm.
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TANIGUCHI ET AL and g-control mice ( Figures 2F and G) . The cell density of the g-conditional transgenic mouse epiphyseal cartilage was significantly decreased compared with that of the gcontrol mouse cartilage ( Figures 2H and I) . Although there were fewer BrdU-positive cells in the g-conditional transgenic mouse cartilage, the percentage of chondrocytes that were BrdU positive did not differ between the 2 genotypes ( Figures 2H and I) . Notably, TUNEL staining showed ectopic apoptosis of chondrocytes in the g-conditional transgenic mouse cartilage ( Figure 2J ). These data indicate that the impaired skeletal growth seen in g-conditional transgenic mouse embryos may be due to ectopic apoptosis and the resulting decrease in chondrocytes caused by the enhanced expression of TAp63g. We then mated p63-flox mice with mice in which an internal ribosome entry site and a Cre recombinase gene were inserted into the 3 0 -untranslated region of the Sox9 gene (Sox9-Cre) (34) to eliminate p63 in chondroprogenitor cells. The conditional knockout mice (Sconditional knockout mice) were born in the expected Mendelian ratios, but all S-conditional knockout neonates died soon after birth for unknown reasons. Sconditional knockout embryos did not show obvious abnormalities in skeletal development compared with p63 fl/fl control littermates ( Figure 3A) . We confirmed efficient deletion of p63 in chondrocytes at both the mRNA and protein levels ( Figures 3B and C) . Histologic analyses including H&E staining, von Kossa's staining, Safranin O staining, and immunofluorescence staining with antibodies to Cola1(X) and MMP-13 showed no obvious difference between S-conditional knockout mice and control littermates (Figures 3D-F) .
We further mated p63-flox mice with Prx1-Cre mice, which express Cre in the mesenchyme of embryonic limb buds (35) . Unlike S-conditional knockout mice, Prx1-Cre;p63 fl/fl (P-conditional knockout) neonates were alive after birth; however, they grew up normally without growth retardation, despite the efficient knockdown of p63 in chondrocytes (Supplementary Figures 4A and B) .
Proapoptotic regulation by p63 and p53 in chondrocytes. Considering the ectopic apoptosis of chondrocytes in g-conditional transgenic mouse limb cartilage and the normal chondrocyte differentiation in S-conditional knockout mouse limb cartilage, we hypothesized that other p53 family members may compensate for the p63 deficiency. In cartilage tissues obtained from g-conditional transgenic mouse embryos, mRNA levels of proapoptotic 
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TANIGUCHI ET AL p53 target genes, including bax, noxa, puma, and fas, were significantly increased ( Figure 4A ). In a-conditional transgenic mouse cartilage tissues, induction of noxa and puma was slight, and that of bax and fas was not significant ( Figure 4A ). We then investigated the expression of p53 and p73 in mouse chondrocytes. Although compensatory up-regulation of p53 was not observed in S-conditional knockout mouse costal chondrocytes, p53 was abundantly expressed at the mRNA level ( Figure 4B ). Meanwhile, p73 expression was hardly detected in either S-conditional knockout or control littermate chondrocytes ( Figure 4B ). Immunostaining showed that p53 protein was expressed abundantly in the hypertrophic zone and weakly in the proliferative zone (Supplementary Figure 5) , similarly to p63 protein ( Figure 1D ). Notably, p53 protein was dominantly localized in the superficial layer of articular cartilage ( Figure 4C ), in contrast to the expression of p63 in the middle layer ( Figure 1E ).
We then examined induction of the proapoptotic genes by p63 and p53 in mouse chondrocytes. When we transfected TAp63a, TAp63g, p53, or GFP into ATDC5 cells, bax, puma, and fas were significantly induced by TAp63g and p53 ( Figure 4D ), similar to the results in gconditional transgenic mouse chondrocytes. Noxa was not detected in ATDC5 cells ( Figure 4D ). To examine whether p53 and p63 share the same response elements in their target genes, we prepared the luciferase reporter constructs containing the proximal promoter regions of BAX, NOXA, PUMA, and FAS. In ATDC5 cells, all promoters were significantly transactivated by TAp63g or p53 ( Figure 4E) . Deletion of the p53 response elements, which have been described previously (36) (37) (38) (39) , markedly decreased the transactivation of the reporters by p63, as well as by p53 (Figure 4E ), indicating that the major response element of p63 was identical to that of p53 in BAX, NOXA, PUMA, and FAS genes. To confirm that transcription of these genes was regulated by both p53 and p63, we knocked down p53 expression by siRNA in S-conditional knockout mice and control littermate chondrocytes. Although the suppression rate of p53 at the mRNA level was ;50%, bax, noxa, and puma were significantly down-regulated by p53 siRNA in S-conditional knockout mouse chondrocytes ( Figure 4F ), indicating that p53 may partially compensate for p63 deficiency.
Suppression of aging-related OA development in P-conditional knockout mice. Since chondrocyte apoptosis is associated with OA development and p63 was expressed in mouse articular cartilage, we investigated whether p63 is involved in the OA process. Since C-conditional knockout mice could not be obtained and S-conditional knockout mice died soon after birth as described above, we examined the articular cartilage of adult P-conditional knockout mice. Eighteen months after birth, P-conditional knockout mice were significantly more resistant to cartilage degeneration than their control littermates ( Figures 5A and B) . The number of chondrocytes in P-conditional knockout mouse knee cartilage was significantly greater than that in control mouse knee cartilage ( Figure 5C ). Notably, both the number and the percentage of TUNEL-positive cells were significantly lower in P-conditional knockout mouse cartilage ( Figures 5A and C) , indicating that p63 is involved in chondrocyte survival in aging mouse articular cartilage. Immunofluorescence staining showed efficient knockout of p63 in the articular cartilage of P-conditional knockout mice ( Figure 5D ).
The expression of p53 was unchanged or slightly up-regulated in P-conditional knockout mouse chondrocytes ( Figure 5D ). MMP-13 and ADAMTS-5, representative catabolic enzymes in cartilage, were detected at a similar level in both mouse genotypes ( Figure 5D ). Because p63 is involved in cellular senescence, we analyzed the expression of senescence marker proteins in articular cartilage; however, we did not observe any clear alterations in the expression of these proteins resulting from p63 knockout (Supplementary Figure 6 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39976/abstract).
Suppression of development of OA caused by surgically induced instability in P-conditional knockout mice. We examined OA development caused by surgically induced joint instability in the control and Pconditional knockout mice (27) . Although OA development was significantly decelerated in the P-conditional knockout mouse surgical model, the difference compared to control mice was smaller than that between Pconditional knockout mice and control mice with age-related OA ( Figures 6A and B) . The number of chondrocytes was significantly larger in the P-conditional knockout mouse knee cartilage than in control mouse knee cartilage, and the number of TUNEL-positive cells was also significantly decreased in the P-conditional knockout mouse articular cartilage ( Figure 6C ). Immunofluorescence staining showed that expression levels of p53, MMP-13, and ADAMTS-5 were not altered ( Figure 6D ).
DISCUSSION
The present study demonstrates that p63 is involved in the regulation of articular cartilage homeostasis in in vivo experiments using p63-conditional knockout mice. The involvement of various factors in OA development, such as catabolic enzymes, inflammatory factors, and endochondral ossification-related molecules, has previously been demonstrated by experiments using mouse models of OA (29, 30, (40) (41) (42) (43) (44) (45) . In the present study chondrocyte apoptosis was suppressed but expression of MMP-13 and ADAMTS-5 was not altered in p63-deficient mouse articular cartilage (Figures 5 and 6) . Although we could not analyze articular cartilage from chondrocyte-specific p63-knockout mice, the phenotype of P-conditional knockout mice was probably caused by a loss of function of p63 in articular chondrocytes because p63 is scarcely expressed in meniscus, synovium, or subchondral bone (Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.39976/abstract). The findings of the present study indicate that, in addition to catabolic enzymes, apoptosis of articular chondrocytes is associated with the pathophysiology of OA.
In the mouse growth plate chondrocytes, however, we could not clearly prove in vivo functions of p63.
Real-time RT-PCR using primer sets specific to each transcript variant revealed that TAp63a and TAp63g are dominantly expressed in costal and articular chondrocytes ( Figure 1B) , in contrast to the abundant expression of the DN isoform in the apical ectodermal ridge (11, 12) . We had initially hypothesized that DNp63, which is expressed in the apical ectodermal ridge, regulates limb generation in an earlier stage, and that TAp63, which is expressed in chondrocytes, regulates limb growth in a later stage. However, the normal skeletal growth of Sconditional knockout mice and P-conditional knockout mice indicates that p63 is dispensable in the growth plate chondrocytes, and that impaired limb development in p63-null mice is caused by p63 deficiency in the apical ectodermal ridge.
Although chondroprogenitor/chondrocyte-specific deletion of p63 did not alter skeletal development, chondrocyte-specific overexpression of TAp63g resulted in impaired skeletal development caused by ectopic apoptosis and the resulting decrease in chondrocytes. Among the p53 family, the construct of TAp63g is most similar to that of p53 (46) . Furthermore, TAp63g shows highest transactivation of a p53 reporter vector among the p63 isoforms (12) . Considering these data and the similar expression of p63 and p53 in the hypertrophic zone, chondrocyte apoptosis there may be regulated by both proteins, and the p63 deficiency during endochondral ossification may be masked by p53. In a previous study, p53-null mice displayed slight dwarfism (47) . Since TUNEL-positive chondrocytes in the hypertrophic zone were reduced by p53 knockout, the authors concluded that the growth defect reflected a delay in cartilage maturation probably caused by reduced apoptosis of chondrocytes (47) . All of these data imply that chondrocyte apoptosis was dominantly regulated by p53, rather than p63. In vitro data in the present study also showed that inductions of bax, puma, and fas by p53 were significantly stronger than that by TAp63g ( Figure  4D ). However, we could not demonstrate the redundancy of p53 and p63 in the regulation of chondrocyte apoptosis during endochondral ossification in vivo. To further investigate the regulation of chondrocyte differentiation by p53 family members, analyses using both p53-and p63-conditional knockout mice are needed.
In contrast to the normal skeletal development of the p63-conditional knockout mice, OA was suppressed by p63 deficiency in both the aging model and the surgical model (Figures 5 and 6) . In articular cartilage, p63 protein was dominantly localized in the middle layer, while p53 protein was in the superficial layer ( Figures 1E  and 4C ). The significant phenotype of OA and the different localization of the 2 proteins imply a unique role of p63 in articular cartilage. Chondrocyte apoptosis was significantly enhanced in both models; however, suppression of OA development by p63 knockout was clearer in the aging model than in the surgical model (Figures 5 and 6 ). These data may imply that p63 plays more pivotal roles in apoptosis associated with aging than in that associated with excessive mechanical loading. We only performed one surgical experiment and only looked at aging mice at one time point, which are limitations of this study.
We examined 4 genes, bax, noxa, puma, and fas, which are proapoptotic transcriptional target genes of p53 and/or p63. Overexpression of TAp63g or p53 induced these genes in primary chondrocytes and ATDC5 cells ( Figure 4D ). They were up-regulated in the g-conditional transgenic mouse cartilage ( Figure 4A ). Fas, known as CD95, is known to be increased in human OA cartilage (6) . Fas is a transcriptional target of hypoxia-inducible factor 2a, and mediates chondrocyte apoptosis during OA development (48) . A SNP in the human FAS gene is also associated with OA susceptibility (49) . PUMA expression is also increased in human OA cartilage (50) . Meanwhile, bax expression in OA cartilage is a subject of controversy (6, 51) . Noxa is induced by reactive oxygen species, which is a representative exacerbation factor in articular cartilage (52) , but its expression in OA cartilage remains unknown. Although the contribution of each molecule to chondrocyte apoptosis is still unknown, all or some of these genes, or other molecules that we did not examine in the present study, may mediate the proapoptotic effect of p63.
Deficiency in p63 induces cellular senescence and accelerates aging in vivo (53) . In the skin, epithelial cells in the basal layer proliferate and provide differentiated keratinocytes that migrate toward the superficial layers (54, 55) . The transcription factor p63 is highly expressed in the basal layer, and its deficiency results in enhanced cellular senescence with increased expression of PML and p16
INK4a (53) . In contrast, in our study p63 deficiency suppressed OA development, and did not clearly alter the expression of PML, p16 INK4a , or other senescence markers (Supplementary Figure 6) . Recently, Kozhemyakina et al showed that progenitors of articular chondrocytes are localized in the superficial zone of articular cartilage (56) . Unlike in the skin, p63 may not regulate the maintenance of chondrocyte progenitors, because p63 expression is not abundant in the superficial zone ( Figure 1E ).
In the present study, p63 protein was intensively detected in the human articular cartilage ( Figure 1F) . Moreover, the recent GWAS from the arcOGEN identified a SNP (rs12107036) associated with OA susceptibility in the human p63 gene (25) . The SNP is located in intron 10 of TAp63a but is not included in the mRNA for p63g. Although the SNP has not been functionally examined yet, it may be involved in the regulation of alternative splicing of the human p63 gene at the Cterminus, and may alter chondrocyte survival and articular cartilage homeostasis in human joints. In conclusion, we demonstrated that p63 is involved in chondrocyte survival in articular cartilage. The findings of the present study may provide a clue to the elucidation of chondrocyte turnover in articular joints.
